Cardiac resynchronization therapy (CRT) is an established treatment for patients with drug-resistant heart failure. CRT provides substantial clinical benefits in patients with systolic heart failure who exhibit evidence of cardiac dyssynchrony and is shown to reduce mortality and hospitalization, reverse cardiac remodeling, and improve functional capacity and quality of life (QOL) [1-3].However, the magnitude of clinical and hemodynamic benefits of CRT varies significantly among recipients [4]. Previous randomized trials demonstrated that QRS morphology and width were the major determinant predictors of CRT response [5]. Based on these results, recent guidelines classified CRT implantation in patients with left bundle branch block (LBBB) and wide QRS [ 4 3 _ T D $ D I F F ] (!150 ms) as class I [6,7]. The efficacy of CRT was found to be inferior in patients with LBBB with moderately wide QRS (120-149 ms), classified as class IIa indication or class I indication with evidence level B. A novel adaptive CRT (aCRT) algorithm that provides ambulatory adjustment of pacing configuration [left ventricle (LV) pacing only or bi-ventricular (BiV) pacing] and AV and VV delays based on